MARKET

LTRN

LTRN

Lantern Pharma Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.50
-0.04
-0.26%
Closed 19:36 01/21 EST
OPEN
15.75
PREV CLOSE
15.54
HIGH
15.76
LOW
14.80
VOLUME
433.25K
TURNOVER
--
52 WEEK HIGH
24.84
52 WEEK LOW
10.40
MARKET CAP
93.47M
P/E (TTM)
-35.5342
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lantern Pharma Announces Closing of Public Offering of $69 Million USD and Full Exercise of Underwriter's Over-Allotment Option
DALLAS, Jan. 20, 2021 /PRNewswire via COMTEX/ -- DALLAS, Jan. 20, 2021 /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company...
PR Newswire - PRF · 1d ago
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 6d ago
Lantern Pharma Priced 4.2M Shares Public Offering @$14/Share
Lantern Pharma (NASDAQ: LTRN) announced the pricing of a public offering of 4,285,715 shares of its common stock at a public offering price of $14.00 per share, for gross proceeds of $60 million, before deducting underwriting discounts and offering expense...
Benzinga · 01/15 10:49
Lantern Pharma prices $60M stock offering
Lantern Pharma (LTRN) has priced its public offering of 4,285,715 common shares at $14.00/share, for gross proceeds of $60M.Underwriters' over-allotment is an additional 642,856 shares. ThinkEquity is acting as sole
Seekingalpha · 01/15 04:30
*DJ Lantern Pharma Offering Expected to Close Jan. 20 >LTRN
Dow Jones · 01/15 02:33
*DJ Lantern Pharma Prices Public Offering of 4,285,715 Shares at $14 Each >LTRN
Dow Jones · 01/15 02:33
Lantern Pharma Announces Pricing of $60 Million Public Offering
, /PRNewswire/ -- Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology...
PR Newswire - PRF · 01/15 02:30
Lantern Pharma Announces Pricing of $60 Million Public Offering
Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharma company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform cancer drug development and identify patients who will benefit from its targeted oncology therapeutics, tod...
PR Newswire · 01/15 02:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LTRN. Analyze the recent business situations of Lantern Pharma Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LTRN stock price target is 27.33 with a high estimate of 29.00 and a low estimate of 25.00.
EPS
Institutional Holdings
Institutions: 13
Institutional Holdings: 160.14K
% Owned: 2.66%
Shares Outstanding: 6.03M
TypeInstitutionsShares
Increased
1
539
New
9
73.87K
Decreased
2
36.42K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.04%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Chairman/Independent Director
Donald Keyser
Chief Financial Officer/Primary Contact
Jeff Thomas
President/Chief Executive Officer/Director
Panna Sharma
Chief Financial Officer/Secretary
David Margrave
Chief Scientific Officer
Kishor Bhatia
Director
David Silberstein
Independent Director
Vijay Chandru
Independent Director
Leslie Kreis
Independent Director
Franklyn Prendergast
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About LTRN
Lantern Pharma Inc. is a clinical stage biotechnology company. The Company is focused on developing oncology therapies. It uses its artificial intelligence (AI) platform, RADR, which includes data points, and uses big data analytics to uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that benefits from its compounds. Its portfolio consists of three compounds: LP-100, LP-300 and LP-184. The Company is developing LP-100 for metastatic, castration-resistant, prostate cancer (mCRPC). LP-300 is a small molecule with cysteine modifying activity on select protein. LP-184, is in a preclinical translational ex vivo study using fresh human biopsies. LP-184 is an alkylating agent with nanomolar potency that preferentially damages deoxyribonucleic acid (DNA) in cancer cells that overexpress certain biomarkers.
More

Webull offers kinds of Lantern Pharma Inc. stock information, including NASDAQ:LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.